巴尔的摩市MSM PrEP使用者性传播感染筛查情况
本研究回顾2015年9月至2018年3月在巴尔的摩市启动PrEP的290名MSM的医疗记录,评估启动时及随访12个月内按指南进行梅毒和淋病/衣原体筛查的比例及阳性率。结果显示启动时仅43.1%按指南筛查,随访期间筛查率更低而梅毒和直肠淋病/衣原体阳性率更高,提示当前筛查策略对STI预防效果可能有限。
要点
- PrEP启动时仅43.1%的MSM按指南完成全面STI筛查。
- 筛查阳性率:梅毒7.8%,直肠淋病11.1%,直肠衣原体11.7%。
- biannual随访时筛查率更低而梅毒和直肠感染阳性率更高。
核心结论
- 观察到的STI筛查水平和疾病负担提示PrEP护理中的STI筛查对STI预防的有效性可能有限。
- 结果提示提供者可能根据性行为提供筛查,需要澄清PrEP使用者的STI筛查指南。
研究设计与样本
- 回顾性队列研究,抽象2015年9月30日至2018年3月31日期间在巴尔的摩市启动PrEP的MSM医疗记录,共290人。
- 计算启动后≤12个月PrEP访视时的STI筛查(梅毒及所有解剖部位的淋病/衣原体)和阳性率。
- 使用带聚类稳健标准误的Poisson回归评估与STI筛查相关的因素。
主要发现
- 启动时按指南筛查的比例为43.1%(125/290)。
- 启动时筛查率:梅毒79.3%(230/290),泌尿生殖道淋病/衣原体69.3%(201/290),直肠55.9%(162/290),口咽69.3%(201/290)。
- 筛查阳性率:梅毒7.8%(18/230);淋病泌尿生殖道5.0%(10/201)、直肠11.1%(18/162)、口咽7.5%(15/201);衣原体泌尿生殖道5.0%(10/201)、直肠11.7%(19/162)、口咽1.5%(3/201)。
- 在 biannual PrEP护理访视时,STI筛查率更低,梅毒和直肠淋病/衣原体阳性率更高。
临床怎么用
- 应提高PrEP使用者按指南进行多部位STI筛查的依从性,尤其在随访期。
- 筛查应基于指南而非仅根据 reported 性行为,以确保高风险人群覆盖。
局限性
- 研究为回顾性医疗记录抽象,可能存在记录不完整或遗漏。
- 样本来自单一城市(巴尔的摩市),结果外推需谨慎。
- 未报告随访期筛查率的具体数值和阳性率数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human immunodeficiency virus pre-exposure prophylaxis (PrEP) clinical guidelines recommend men who have sex with men (MSM) PrEP users be screened biannually for syphilis and gonorrhea/chlamydia at all anatomic sites. We sought to determine the proportion screened and positive by STI and anatomic site at PrEP initiation and PrEP-care visits and patient-level characteristics associated with screening among MSM PrEP users in Baltimore City, Maryland. METHODS: Medical records among MSM initiating PrEP between 30 September 2015 and 31 March 2018 were abstracted. STI screening (syphilis and gonorrhea/chlamydia at all anatomic sites) and positivity at PrEP visits ≤12 months following initiation were calculated. Poisson regression with cluster robust SEs was used to assess associations with STI screening. RESULTS: Among 290 MSM initiating PrEP, 43.1% (n = 125) were screened per guidelines at PrEP initiation; 79.3% (230), 69.3% (201), 55.9% (162), and 69.3% (201) were screened for syphilis, urogenital, rectal, and oropharyngeal gonorrhea/chlamydia, respectively. Positivity among those screened was syphilis, 7.8% (n = 18/230); gonorrhea, 5.0% urogenital (10/201), 11.1% rectal (18/162), and 7.5% oropharyngeal (15/201); chlamydia, 5.0% urogenital (10/201), 11.7% rectal (19/162), and 1.5% oropharyngeal (3/201). Reported anal and oral sex (vs neither) was independently associated with STI screening (aPR, 2.11; 1.05-4.27) at PrEP initiation. At biannual PrEP-care visits, STI screening was lower and syphilis and rectal gonorrhea/chlamydia positivity was higher. CONCLUSIONS: Observed STI screening levels and disease burden suggest the effectiveness of STI screening in PrEP care for STI prevention may be limited. Our results suggest providers may be offering screening based on sexual practices; clarification of STI screening guidelines for PrEP users is needed.
引用
- Schumacher C, Wu L, Chandran A, et al. Sexually Transmitted Infection Screening Among Gay, Bisexual, and Other Men Who Have Sex With Men Prescribed Pre-exposure Prophylaxis in Baltimore City, Maryland. Clin Infect Dis. 2020. PMID: 31761944. doi:10.1093/cid/ciz1145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。